Back to search

Poland· PL-100123478

Cefotaxim-MIP 1 g

A cefotaxime product containing cefotaximum, registered in Poland by MIP Pharma Polska Sp. z o.o.. The same ATC class is registered in 18 of our 19 countries.

ATC J01DD01

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedCefotaxim-MIP 1 gATCJ01DD01REGISTER NO.PL-100123478PACKS LISTED4CHECKEDSeptember 27, 2026

Where it is registered

Cefotaxime is registered in 18 of 19 countries.

Countries holding a registration under ATC J01DD01 (cefotaxime), each read from that country’s own register.

  • This record: Poland, from URPL (Poland)
  • 10 of them publish a price we can compare per daily dose

Cefotaxime · ATC J01DD01

18 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Germany
  • Icelandprice
  • Ireland
  • Italyprice
  • Japan
  • Netherlands
  • Norwayprice
  • Polandprice
  • Spainprice
  • Sweden
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of cefotaxime costs, country by country.

Normalised to the WHO defined daily dose (4 g), so markets compare like for like.

  • 1 market with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown

Cefotaxime · price per daily dose (4 g)

USD · FX 28 Sept 2026

  • ES Spain$14.21
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

URPL (Poland)
Active substance
Cefotaximum
Manufacturer
MIP Pharma Polska Sp. z o.o.
Country
Poland (PL)
ATC code
J01DD01
ATC class
Cefotaxime
Defined daily dose
4 g, P
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 27, 2026

Packs & prices · 4

  • gtin
    05909991058715
  • gtin
    05909991058722
  • gtin
    05909991058739
  • gtin
    05909991058746

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

104 interactions on record for cefotaxime.

Graded by severity as the source publishes them — 21 moderate. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Cefotaxime · interactions on record

104 records

  • 21 moderate
  • 83 info

Most severe, free to view

  • Sodium picosulfateA06AB08moderate
  • NeomycinA07AA01moderate
  • StreptomycinA07AA04moderate
  • KanamycinA07AA08moderate
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Cefotaxime in 15 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All cefotaxime products

Authorised across Europe · EMA

The same active substance is authorised in 29 EEA countries. Names it is sold under:

  • Austria · Cefotaxim Aptapharma, Cefotaxim Eberth
  • Belgium · Cefotaxime Noridem, Claforan
  • Bulgaria · Валоран, Тенатаксим
  • Cyprus · Oximezin, Syntoxime
  • Czechia · Cefotaxim Hameln, Cefotaxime Swyssi
  • Germany · Cefotaxim Eberth, Cefotaxim Fresenius
  • Denmark · Cefotaxim "hameln", Cefotaxim Mip
  • Estonia · Cefotaxime Mip, Valoran
  • Spain · Cefotaxima Normon, Cefotaxima Sala
  • Finland · Cefotaxim Hameln, Cefotaxim Mip Pharma
  • France · Cefotaxime Noridem, Cefotaxime Panpharma
  • United Kingdom (Northern Ireland) · Cefotaxime Cox Pharmaceutical, Cefotaxime Hameln Pharma
  • Greece · Ciltiren, Gloryfen
  • Croatia · Cefotaksim Aptapharma, Cefotaksim Mip
  • Hungary · Cefotaxim Aptapharma, Cefotaxime Swyssi
  • Ireland · Cefotaxime Hameln, Cefotaxime Noridem Enterprises
  • Iceland · Cefotaxim Navamedic
  • Italy · Batixim, Cefotaxim Hameln
  • Lithuania · Cefotaxime Mip
  • Luxembourg · Cefotaxime Noridem, Claforan
  • Latvia · Cefotaxime Mip
  • Malta · Valoran
  • Netherlands · Cefotaxim Hameln
  • Norway · Cefotaxim Hameln, Cefotaxim Mip
  • Portugal · Antadar, Antadar I.M.
  • Romania · Cefotax, Cefotaxim Mip
  • Sweden · Cefotaxim Hameln, Cefotaxim Mip
  • Slovenia · Cefotaksim Aptapharma, Valoran
  • Slovakia · Cefotaxim Eberth, Cefotaxime Hameln

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/cadf5852-a1f5-4966-8c36-67cf5a977645
GET /v1/drugs/cadf5852-a1f5-4966-8c36-67cf5a977645?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Proszek do sporządzania roztworu do wstrzykiwań i infuzji",
  "source": "urpl",
  "strength": "1 g",
  "packaging": "05909991058715 ¦ Lz ¦ 19388\n1 fiol. 10 ml\n05909991058722 ¦ Lz ¦ 23261\n5 fiol. 10 ml\n05909991058739 ¦ Lz ¦ 57969\n10 fiol. 10 ml\n05909991058746 ¦ Lz ¦ 58071\n25 fiol. 10 ml",
  "substance": "Cefotaximum 1 g",
  "common_name": "Cefotaximum",
  "pl_product_id": "100123478",
  "pozwolenie_nr": "10587",
  "auth_procedure": "NAR",
  "authorisation_validity": "Bezterminowe"
}

See everything about cefotaxime.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.